Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies

  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Oncology Letters
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-1074 Online ISSN: 1792-1082
Journal Cover
November 2012 Volume 4 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November 2012 Volume 4 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Carboplatin and bevacizumab for recurrent malignant glioma

  • Authors:
    • Maciej M. Mrugala
    • Laurie K. Crew
    • James R. Fink
    • Alexander M. Spence

  • View Affiliations / Copyright

    Affiliations: Department of Neurology, University of Washington Medical School, Seattle, WA 98195, USA, Department of Neurosurgery, University of Washington Medical School, Seattle, WA 98195, USA, Department of Radiology, University of Washington Medical School, Seattle, WA 98195, USA, Department of Neurology, University of Washington Medical School, Seattle, WA 98195, USA
  • Pages: 1082-1086
    |
    Published online on: August 1, 2012
       https://doi.org/10.3892/ol.2012.839
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Over 65,000 primary brain tumors are diagnosed annually in the US alone. Malignant gliomas represent more than one-third of such cases. Despite advances in neuroimaging, surgical techniques, radiotherapy and chemotherapy, the survival rate of this disease remains poor. The introduction of agents which disrupt the function of vascular endothelial growth factor (VEGF) and its receptors to glioma therapy has resulted in an unusually high percentage of patients experiencing radiographic responses. Bevacizumab, approved by the Food and Drug Administration for the treatment of recurrent glioblastoma in 2009, has changed the field of neuro-oncology. The drug has been utilized as a single agent and in combination with the classic cytotoxic agents typically applied in this setting. Numerous studies have reported high response rates and encouraging extensions of time-to-progression. The optimal schedule and combination of bevacizumab with alternative drugs has not been identified. The current study presents the results of a retrospective analysis of the combination therapy utilizing bevacizumab with the alkylating agent carboplatin in patients with recurrent malignant glioma.
View Figures

Figure 1

Figure 2

Figure 3

View References

1. 

R StuppWP MasonMJ van den BentM WellerB FisherMJ TaphoornK BelangerRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med352987996200510.1056/NEJMoa04333015758009

2. 

D FultonR UrtasunP ForsythPhase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant gliomaJ Neurooncol27149155199610.1007/BF001774788699237

3. 

HS FriedmanWP PetrosAH FriedmanLJ SchaafT KerbyJ LawyerM ParryIrinotecan therapy in adults with recurrent or progressive malignant gliomaJ Clin Oncol1715161525199910334539

4. 

WK YungRE AlbrightJ OlsonR FredericksK FinkMD PradosM BradaA phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBr J Cancer83588593200010.1054/bjoc.2000.131610944597

5. 

RE WarnickMD PradosEE MackKL ChandlerF DozJE RabbittMK MalecA phase II study of intravenous carboplatin for the treatment of recurrent gliomasJ Neurooncol196974199410.1007/BF010510507815106

6. 

Y WangD FeiM VanderlaanA SongBiological activity of bevacizumab, a humanized anti-VEGF antibody in vitroAngiogenesis7335345200410.1007/s10456-004-8272-215886877

7. 

V Stark-VanceBevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Abstracts from the World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-OncologyNeuro-Oncol7abstract 3422005

8. 

JJ VredenburghA DesjardinsJE Herndon IIJ MarcelloDA ReardonJA QuinnJN RichBevacizumab plus irinotecan in recurrent glioblastoma multiformeJ Clin Oncol2547224729200710.1200/JCO.2007.12.244017947719

9. 

JJ VredenburghA DesjardinsJE Herndon IIJM DowellDA ReardonJA QuinnJN RichPhase II trial of bevacizumab and irinotecan in recurrent malignant gliomaClin Cancer Res1312531259200710.1158/1078-0432.CCR-06-230917317837

10. 

HS FriedmanMD PradosPY WenT MikkelsenD SchiffLE AbreyWK YungBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol2747334740200910.1200/JCO.2008.19.872119720927

11. 

TN KreislL KimK MooreP DuicC RoyceI StroudN GarrenPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol27740745200910.1200/JCO.2008.16.305519114704

12. 

DA ReardonA DesjardinsJJ VredenburghS GururanganJH SampsonS SathornsumeteeRE McLendonMetronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II studyBr J Cancer10119861994200910.1038/sj.bjc.660541219920819

13. 

S SathornsumeteeA DesjardinsJJ VredenburghRE McLendonJ MarcelloJE HerndonA MathePhase II trial of bevacizumab and erlotinib in patients with recurrent malignant gliomaNeuro Oncol1213001310201020716591

14. 

A DesjardinsDA ReardonA CoanJ MarcelloJE Herndon IIL BaileyKB PetersBevacizumab and daily temozolomide for recurrent glioblastomaCancer11813021312201210.1002/cncr.2638121792866

15. 

DA ReardonA DesjardinsKB PetersS GururanganJH SampsonRE McLendonJE Herndon IIPhase II study of carboplatin, irinotecan and bevacizumab for bevacizumab naïve, recurrent glioblastomaJ Neurooncol107155164201221986722

16. 

AB FrancesconiS DupreM MatosD MartinBG HughesDK WyldJD LickliterCarboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiformeJ Clin Neurosci17970974201010.1016/j.jocn.2009.12.00920541421

17. 

EM ThompsonE DosaDF KraemerEA NeuweltTreatment with bevacizumab plus carboplatin for recurrent malignant gliomaNeurosurgery678793201010.1227/01.NEU.0000370918.51053.BC20559095

18. 

WK YungL MechtlerMJ GleasonIntravenous carboplatin for recurrent malignant glioma: a phase II studyJ Clin Oncol986086419911849986

19. 

B JeremicD GrujicicS JevremovicB StanisavljevicL MilojevicL DjuricL MijatovicCarboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II studyJ Clin Oncol101074107719921318951

20. 

RK JainNormalization of tumor vasculature: an emerging concept in antiangiogenic therapyScience3075862200510.1126/science.110481915637262

21. 

RK JainAntiangiogenic therapy for cancer: current and emerging conceptsOncology (Williston Park)19716200515934498

22. 

AD NordenGS YoungK SetayeshA MuzikanskyR KlufasGL RossAS CiampaBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology70779787200810.1212/01.wnl.0000304121.57857.3818316689

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Mrugala MM, Crew LK, Fink JR and Spence AM: Carboplatin and bevacizumab for recurrent malignant glioma. Oncol Lett 4: 1082-1086, 2012.
APA
Mrugala, M.M., Crew, L.K., Fink, J.R., & Spence, A.M. (2012). Carboplatin and bevacizumab for recurrent malignant glioma. Oncology Letters, 4, 1082-1086. https://doi.org/10.3892/ol.2012.839
MLA
Mrugala, M. M., Crew, L. K., Fink, J. R., Spence, A. M."Carboplatin and bevacizumab for recurrent malignant glioma". Oncology Letters 4.5 (2012): 1082-1086.
Chicago
Mrugala, M. M., Crew, L. K., Fink, J. R., Spence, A. M."Carboplatin and bevacizumab for recurrent malignant glioma". Oncology Letters 4, no. 5 (2012): 1082-1086. https://doi.org/10.3892/ol.2012.839
Copy and paste a formatted citation
x
Spandidos Publications style
Mrugala MM, Crew LK, Fink JR and Spence AM: Carboplatin and bevacizumab for recurrent malignant glioma. Oncol Lett 4: 1082-1086, 2012.
APA
Mrugala, M.M., Crew, L.K., Fink, J.R., & Spence, A.M. (2012). Carboplatin and bevacizumab for recurrent malignant glioma. Oncology Letters, 4, 1082-1086. https://doi.org/10.3892/ol.2012.839
MLA
Mrugala, M. M., Crew, L. K., Fink, J. R., Spence, A. M."Carboplatin and bevacizumab for recurrent malignant glioma". Oncology Letters 4.5 (2012): 1082-1086.
Chicago
Mrugala, M. M., Crew, L. K., Fink, J. R., Spence, A. M."Carboplatin and bevacizumab for recurrent malignant glioma". Oncology Letters 4, no. 5 (2012): 1082-1086. https://doi.org/10.3892/ol.2012.839
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team